Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer
Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer
This is a feasibility study to gain preliminary information regarding whether breast imaging
 with or without a core needle biopsy after neoadjuvant chemotherapy (NAC) but before surgery
 can accurately predict complete pathologic response (pCR) in women with triple negative or
 HER2- positive breast cancer. pCR is defined as having no residual invasive breast cancer or
 ductal carcinoma in situ.
Inclusion Criteria:

 -  Biopsy proven triple negative (TN) (ER-/PR-/HER2-) or HER2 positive
 (ERany/PRany/HER2+) breast cancer for which neoadjuvant chemotherapy is planned

 -  A biopsy clip placed at the time of diagnostic biopsy

 -  18 years of age or older

 -  Must be able to read and write in English due to the importance of survey
 (questionnaire) completion to meet the study's endpoint - this is justified as there
 is no individual benefit to study participation

 -  Able to provide written consent prior to any research related activities

 Exclusion Criteria:

 -  Stage IV breast cancer

 -  T4 breast cancer

 -  Previous ipsilateral breast cancer

 -  Any contraindication for undergoing a contrast-enhanced breast MRI and/or the breast
 biopsy between chemotherapy and surgery